Compare VRTX & PLPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRTX | PLPC |
|---|---|---|
| Founded | 1989 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Water Sewer Pipeline Comm & Power Line Construction |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.6B | 987.1M |
| IPO Year | 1991 | N/A |
| Metric | VRTX | PLPC |
|---|---|---|
| Price | $452.25 | $232.09 |
| Analyst Decision | Buy | |
| Analyst Count | 25 | 0 |
| Target Price | ★ $494.64 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 70.2K |
| Earning Date | 11-03-2025 | 10-29-2025 |
| Dividend Yield | N/A | ★ 0.34% |
| EPS Growth | N/A | ★ 13.62 |
| EPS | ★ 14.22 | 7.55 |
| Revenue | ★ $11,723,300,000.00 | $663,346,000.00 |
| Revenue This Year | $11.01 | $16.31 |
| Revenue Next Year | $8.74 | $13.74 |
| P/E Ratio | $31.78 | ★ $30.95 |
| Revenue Growth | 10.33 | ★ 15.93 |
| 52 Week Low | $362.50 | $118.99 |
| 52 Week High | $519.68 | $245.99 |
| Indicator | VRTX | PLPC |
|---|---|---|
| Relative Strength Index (RSI) | 59.92 | 65.83 |
| Support Level | $433.81 | $200.62 |
| Resistance Level | $463.85 | $238.90 |
| Average True Range (ATR) | 10.71 | 7.64 |
| MACD | 0.51 | 3.50 |
| Stochastic Oscillator | 72.53 | 83.20 |
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Preformed Line Products Co is a designer and manufacturer of products and systems for constructing and maintaining overhead and underground networks for energy, telecommunication, cable operators, data communication, and other industries. In addition, it provides solar hardware systems and mounting hardware for a variety of solar power applications. Its products consist of Energy Products, Communications Products, and Special Industries Products. The company's majority of the revenue is derived from the sale of products in The Americas with operations also in PLP-USA, Europe, the Middle East and Africa, and Asia-Pacific. The revenue gets driven by Energy products which comprise protecting transmission conductors, spacers, spacer-dampers, and Stockbridge dampers.